Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Sorrento Therpt (SRNE)

Sorrento Therpt (SRNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,334,123
  • Shares Outstanding, K 298,100
  • Annual Sales, $ 39,990 K
  • Annual Income, $ -298,460 K
  • 60-Month Beta 2.35
  • Price/Sales 60.24
  • Price/Cash Flow N/A
  • Price/Book 14.07
Trade SRNE with:

Options Overview Details

View History
  • Implied Volatility 70.93%
  • Historical Volatility 38.58%
  • IV Percentile 1%
  • IV Rank 2.04%
  • IV High 242.39% on 01/27/21
  • IV Low 67.36% on 09/23/21
  • Put/Call Vol Ratio 0.11
  • Today's Volume 13,521
  • Volume Avg (30-Day) 9,460
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 223,086
  • Open Int (30-Day) 236,846

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.21
  • Number of Estimates 3
  • High Estimate -0.17
  • Low Estimate -0.29
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +36.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.77 +4.50%
on 09/15/21
9.31 -12.78%
on 09/02/21
-1.03 (-11.26%)
since 08/27/21
3-Month
7.69 +5.56%
on 07/15/21
11.07 -26.65%
on 07/01/21
-1.74 (-17.65%)
since 06/25/21
52-Week
5.17 +57.06%
on 11/10/20
17.25 -52.93%
on 02/08/21
-1.52 (-15.72%)
since 09/25/20

Most Recent Stories

More News
Dr. Henry Ji, Sorrento Chairman and CEO, to Participate in the Virtual Cantor Global Healthcare Conference on September 29th, 2021

Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that it will participate in the Cantor Virtual Healthcare Conference.

SRNE : 8.14 (+3.96%)
Accelerated Development of COVID-19 Vaccines to Combat Potential for Possible Future Viral Pathogens and Variants - Financial News Media

Palm Beach, FL - September 22, 2021 - FinancialNewsMedia.com News Commentary – The U.S. government, via the American Rescue Plan, is investing more than $3 billion to accelerate the discovery, development...

QBIO : 0.6836 (-1.64%)
CRVS : 7.67 (+12.79%)
MRNA : 408.84 (-4.95%)
SRNE : 8.14 (+3.96%)
CYDY : 2.2850 (-1.51%)
Accelerated Development of COVID-19 Vaccines to Combat Potential for Possible Future Viral Pathogens and Variants

PALM BEACH,  Fla., /PRNewswire/ -- The U.S. government, via the American Rescue Plan, is investing more than to accelerate the discovery, development and manufacturing of antiviral medicines as part...

QBIO : 0.6836 (-1.64%)
CRVS : 7.67 (+12.79%)
MRNA : 408.84 (-4.95%)
SRNE : 8.14 (+3.96%)
CYDY : 2.2850 (-1.51%)
Oncolytic Virotherapy Market- Sales Outlook, Up-to-date Development Data and Market Trends Forecast 2029

Research Nester released a report titled ": Global Demand Analysis & Opportunity Outlook 2029"which delivers detailed overview of the oncolytic virotherapy marketn terms of market segmentation by cancer...

AMGN : 213.11 (-0.23%)
SRNE : 8.14 (+3.96%)
Sorrento Announces an Independent Real-World Study That Reports Superior Sensitivity Results in Detecting COVID-19 Virus Infections in All-Comer General Population by COVISTIX as Compared to a Globally Leading Rapid Antigen Test

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease...

SRNE : 8.14 (+3.96%)
Why Experts Believe Antibody Treatments Hold The Potential To Reduce Need For Hospitalization For COVID-19 Patients - Financial News Media

Palm Beach, FL - September 14, 2021 – FinancialNewsMedia.com News Commentary – All across the globe, innumerable scientists are looking to beat COVID-19... the two main paths are to find better vaccines...

BIOV.CN : 0.465 (-6.06%)
BVAXF : 0.3866 (-2.23%)
SRNE : 8.14 (+3.96%)
BNTX : 307.09 (-7.91%)
CYDY : 2.2850 (-1.51%)
NVAX : 231.04 (-6.90%)
Why Experts Believe Antibody Treatments Hold The Potential To Reduce Need For Hospitalization For COVID-19 Patients

/PRNewswire/ --  - All across the globe, innumerable scientists are looking to beat COVID-19… the two main paths are to find better vaccines and to utilize better treatments. As with most viruses, developing...

BIOV.CN : 0.465 (-6.06%)
BVAXF : 0.3866 (-2.23%)
SRNE : 8.14 (+3.96%)
BNTX : 307.09 (-7.91%)
CYDY : 2.2850 (-1.51%)
NVAX : 231.04 (-6.90%)
Dr. Henry Ji, Sorrento Chairman and CEO, to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the H.C. Wainwright 23 Global Investment Conference (www.hcwevents.com/annualconference)....

SRNE : 8.14 (+3.96%)
The Vaccine Revolution Portfolio (MRNA, PFE, JNJ, NVAX, BNTX, AZN, DYAI)

JNJ : 163.17 (-0.72%)
SRNE : 8.14 (+3.96%)
DYAI : 5.90 (+2.97%)
NVAX : 231.04 (-6.90%)
MRNA : 408.84 (-4.95%)
PFE : 43.57 (-0.84%)
BNTX : 307.09 (-7.91%)
AZN : 58.72 (-2.70%)
New Strong Sell Stocks for September 8th

AU, INTZ, RIO, SRNE, and PRTH have been added to the Zacks Rank #5 (Strong Sell) List on September 8, 2021

RIO : 67.54 (+1.15%)
AU : 15.40 (+0.72%)
INTZ : 4.23 (-5.37%)
SRNE : 8.14 (+3.96%)
PRTH : 7.09 (-7.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sorrento Therapeutics, Inc. is a biopharmaceutical company. It is focused primarily on the acquisition, discovery, development and commercialization of proprietary oncology therapeutics. The Company researches human therapeutic antibodies for the treatment of cancer, inflammation, metabolic disease and...

See More

Key Turning Points

3rd Resistance Point 8.25
2nd Resistance Point 8.16
1st Resistance Point 8.00
Last Price 8.14
1st Support Level 7.75
2nd Support Level 7.66
3rd Support Level 7.50

See More

52-Week High 17.25
Fibonacci 61.8% 12.64
Fibonacci 50% 11.21
Fibonacci 38.2% 9.78
Last Price 8.14
52-Week Low 5.17

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar